Anticonvulsant Market Analysis, Region & Country Revenue Share, & Forecast Till 2032

The global anticonvulsants market size was USD 18.57 Billion in 2022 and is expected to register a revenue CAGR of 2.5% during the forecast period.


The global Anticonvulsant Market size was USD 18.57 Billion in 2022 and is expected to register a revenue CAGR of 2.5% over the forecast period, according to the latest report by Reports and Data. Revenue growth of the market is expected to be driven by government programs that support drug development and marketing including funds and investments.

People are more likely to suffer from depression and other mental health conditions. Also, they are growing lot healthier and are beginning to understand the value of non-pharmaceutical, non-invasive therapies in the fight against such illnesses. Five males between the ages of 15 and 19 were reported by UNICEF to have a mental disorder in Europe, compared to more than 16% of females in the same age range. More than half of the 9 million children (10–19) with mental health difficulties suffer from anxiety and stress. The market is expanding as a result of regulatory agencies approving more drugs. As an illustration, the pharmaceutical company Lupin announced on March 24, 2022, that the Food and Drug Administration (FDA) had authorised their Abbreviated New Drug

Download sample @

Some Key Highlights From the Report

  • The second-generation segment is expected to account for largest revenue share over the forecast period. Factors such as enhanced tolerance reduced adverse effects, and increased efficacy is driving the revenue growth of this segment. The number of medicines available to treat seizure disorders has doubled as a result of the inclusion of these second-generation drugs. These include zonisamide, gabapentin (Neurontin), levetiracetam (Keppra), felbamate (Felbatol), lamotrigine (Lamictal), oxcarbazepine (Trileptal), gabapentin (Neurontin) (Zonegran), and tiagabine (Gabitril).
  • The capsule segment is expected to register a significantly fast revenue growth rate over the forecast period. Individuals are more likely to accept capsules since they have no taste or odor. Patient compliance is much improved by capsules, which also improves treatment outcomes If a patient has trouble swallowing, it can be helpful for them to open the capsule and spread the contents on food like applesauce.
  • The hospital segment is expected to account for a major revenue share over the forecast period. Factors such as an increase in the number of pharmacies in hospitals that cater to psychiatric, neurological, and other areas of medicine, lower treatment costs, and a rise in the prevalence of mental health problems globally. Services for both serious and complicated diseases are continuously offered. To better meet patient needs and increase therapeutic effectiveness, hospitals engage in Research and Development (RD). They concentrate their limited resources on effective referral systems.
  • The market in North America accounted for the largest revenue share in 2022. Factors such as increased public awareness of mental health issues, an increase in these disorders, corporate RD efforts, and drug approvals are major factors contributing to market revenue growth in this region. Rising treatment and disease diagnosis rates of neurological conditions, along with an increasing number of awareness campaigns regarding the availability of unique drugs and treatment options, as well as the presence of favorable reimbursement policies in this region are expected to drive market revenue growth in this region.


Key Companies Operating in the Industry are:

Pfizer Inc., Johnson Johnson Services, Inc., Abbott, Novartis AG, Jazz Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Cephalon, Sunovion Pharmaceuticals Inc., Eisai Co., Ltd. and among others.

Drug Type Outlook (Revenue, USD Billion; 2019-2032)

  • Barbiturate
  • α-Amino-3-Hydroxy-5-Methyl-4-isoxazole Propionic acid (AMPA)
  • Carbamate Anticonvulsant Energy Management
  • Carbonic Anhydrase Inhibitor
  • Valproylamides (Amide Valproate)
  • Others

Application (Revenue, USD Billion; 2019-2032)

  • Epilepsy
  • Fibromyalgia
  • Neuropathic Pain
  • Anxiety
  • Migraine
  • Bipolar Disorder
  • Borderline Personality Disorder
  • Others

Drug Generation (Revenue, USD Billion; 2019-2032)

  • First Generation
  • Second Generation
    • Third Generation

Dosage (Revenue, USD Billion; 2019-2032)

  • Capsule
  • Tablet
  • Cream
  • Liquid
  • Rectal Gel
  • Others

End-Use (Revenue, USD Billion; 2019-2032)

  • Hospitals
  • Clinics
  • Ambulatory Surgical Clinics
  • Others

Regional Analysis of the Anticonvulsant Market Includes:

  • North America (U.S., Canada, Mexico)
  • Europe (U.K., Italy, Germany, France, BENELUX, Italy, Rest of Europe)
  • Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

To know more about the report @ URL  

Key Objectives of the Global Anticonvulsant Market Report:

  • Offers a comprehensive overview of the Anticonvulsant market along with product portfolio and supply chain assessment
  • In-depth study of market drivers, constraints, suppliers and distributors, limitations, opportunities, marketing and production, and other key segments
  • SWOT analysis and Porter’s Five Forces analysis to offer accurate insights
  • Complete analysis of the competitive landscape including expansion strategies, product portfolio, production capacity, and strategic initiatives

Request a customization of the report @

Thank you for reading our report. To know more about the customization of the report, please get in touch with us and our team will ensure the report is suited to your requirements.

Get Explore Latest Research Report by Reports and Data:

Wearable Patient Sensor Market @

Respiratory Care Devices Market @

Surgical Camera Market @

Surgical Lights Market @

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

Head of Business Development

Reports and Data | Web:

Direct Line: +1-212-710-1370